Cancer Drugs Under Development

Publication
Article
OncologyONCOLOGY Vol 9 No 2
Volume 9
Issue 2

According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.

According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.

Articles in this issue
New Noninvasive Test May Improve Breast Cancer Diagnosis and Reduce Unnecessary Biopsies
Cancer Drugs Under Development
Early Results of RTOG Small-Cell Lung Cancer Trial
The Economics of Oncology: Health System Reform and Clinical Research
An Update on the Pros and Cons of Preventive Mastectomy
The Effect of Tamoxifen on the Endometrium
Commentary (Look): The Effect of Tamoxifen on the Endometrium
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium
Management of Papillary Thyroid Cancer
Commentary (Cady): Management of Papillary Thyroid Cancer
The Management of Early Ovarian Cancer
Commentary (Markman): The Management of Early Ovarian Cancer
Commentary (Thigpen): The Management of Early Ovarian Cancer
Recent Videos
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
9 Experts are featured in this series.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
9 Experts are featured in this series.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
Related Content
Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase

Ariana Pelosci
November 14th 2024
Article

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Belantamab Mafodotin Combo Significantly Improves OS in Multiple Myeloma

Russ Conroy
November 14th 2024
Article

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Denileukin Diftitox Combo Shows Promising ORR and CBR in Solid Tumors

Tim Cortese
November 14th 2024
Article

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Transposon-Engineered BAFF CAR-T Cells May Elicit Responses in Lymphoma

Roman Fabbricatore
November 13th 2024
Article

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.